Literature DB >> 26945884

Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis.

Vincent Navarro1, Aurélie Kas2, Emmanuelle Apartis3, Linda Chami4, Véronique Rogemond4, Pierre Levy5, Dimitri Psimaras6, Marie-Odile Habert2, Michel Baulac7, Jean-Yves Delattre6, Jérome Honnorat4.   

Abstract

Encephalitis associated with antibodies against leucine-rich glioma-inactivated 1 (LGI1) protein is increasingly recognized as an auto-immune disorder associated with characteristic tonic-dystonic seizures. The cortical or subcortical origin of these motor events is not clear. Some patients also present with different epileptic seizures and with cognitive impairment. The frequency of these features and their timing during the natural history of this encephalitis have not been fully described. We therefore reviewed data from 34 patients harbouring antibodies against LGI1 protein (21-81 years, median age 64) referred to the French Reference Centre for Neurological Paraneoplastic Syndrome. Three types of evidence suggested tonic-dystonic seizures were of cortical origin: (i) a slow, unilateral, frontal electroencephalographic wave, of duration ∼580 ms and amplitude ∼71 µV, preceded the contralateral tonic-dystonic seizures in simultaneous electroencephalographic and myographic records from seven of seven patients tested; (ii) 18-Fluorodeoxyglucose imaging revealed a strong hypermetabolism in primary motor cortex, controlateral to the affected limb, during encephalitis for five patients tested, as compared with data from the same patients after remission or from 16 control subjects; and (iii) features of polymyographic records of tonic-dystonic seizure events pointed to a cortical origin. Myoclonic patterns with brief, rhythmic bursts were present in three of five patients tested and a premyoclonic potential was identified in the cortex of one patient. Initially during encephalitis, 11 of 34 patients exhibited tonic-dystonic seizures (32%). Distinct epileptic syndromes were evident in 13 patients (38%). They were typically simple, focal seizures from the temporal lobe, consisting of vegetative symptoms or fear. At later stages, 22 of 32 patients displayed tonic-dystonic seizures (68%) and 29 patients presented frequent seizures (91%) including status epilepticus. Cognitive impairment, either anterograde amnesia or confusion was evident in 30 of 34 patients (88%). Brain imaging was normal in patients with isolated tonic-dystonic seizures; in patients with limbic symptoms it revealed initially a hippocampal hyperintensity in 8 of 19 patients (42%) and 17 of 24 patients (70%) at later stages. Our data suggest that the major signs of LGI1-antibody encephalitis can be linked to involvement of motor cortex and hippocampus. They occur in parallel with striatum involvement. One of these cortical targets is involved, often unilaterally at disease onset. As the encephalitis progresses, in the absence of immunomodulatory treatment, the second cortical target is affected and effects become bilateral. Progression to the second cortical target occurs with a variable delay of days to several months.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  LGI1; encephalitis; epilepsy; hippocampus; tonic seizure

Mesh:

Substances:

Year:  2016        PMID: 26945884     DOI: 10.1093/brain/aww012

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  44 in total

1.  Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis.

Authors:  Alberto Vogrig; Giada Pauletto; Christian Lettieri; Mariarosaria Valente; Gian Luigi Gigli
Journal:  Neurol Sci       Date:  2019-02-07       Impact factor: 3.307

Review 2.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Authors:  Josep Dalmau; Christian Geis; Francesc Graus
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 3.  Autoimmune seizures and epilepsy.

Authors:  Christian Geis; Jesus Planagumà; Mar Carreño; Francesc Graus; Josep Dalmau
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

4.  Drop attacks: A clinical manifestation of LGI1 encephalitis.

Authors:  Ana Vives-Rodriguez; Adithya Sivaraju; Elan D Louis
Journal:  Neurol Clin Pract       Date:  2017-10

5.  Faciobrachial Dystonic Seizures: The Borderland Between Epilepsy and Movement Disorders.

Authors:  Alessandra Morano; Martina Fanella; Anna Teresa Giallonardo; Carlo Di Bonaventura
Journal:  Mov Disord Clin Pract       Date:  2020-01-08

6.  Volumetry of Mesiotemporal Structures Reflects Serostatus in Patients with Limbic Encephalitis.

Authors:  L Ernst; B David; J Gaubatz; I Domínguez-Narciso; G Lüchters; A J Becker; B Weber; E Hattingen; C E Elger; T Rüber
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-14       Impact factor: 3.825

7.  Clinical and genetic characteristics of type I sialidosis patients in mainland China.

Authors:  Rui-Juan Lv; Tao-Ran Li; Yu-Di Zhang; Xiao-Qiu Shao; Qun Wang; Li-Ri Jin
Journal:  Ann Clin Transl Neurol       Date:  2020-05-29       Impact factor: 4.511

8.  Recurrent seizures of autoimmune origin: emerging phenotypes.

Authors:  Mathilde Goudot; Solène Frismand; Lucie Hopes; Antoine Verger; Bastien Joubert; Jérôme Honnorat; Louise Tyvaert
Journal:  J Neurol       Date:  2021-02-27       Impact factor: 4.849

Review 9.  Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis.

Authors:  Marianna Spatola; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2017-06       Impact factor: 5.710

10.  A two-site, open-label, non-randomized trial comparing Focal Electrically-Administered Seizure Therapy (FEAST) and right unilateral ultrabrief pulse electroconvulsive therapy (RUL-UBP ECT).

Authors:  Gregory L Sahlem; William V McCall; E Baron Short; Peter B Rosenquist; James B Fox; Nagy A Youssef; Andrew J Manett; Suzanne E Kerns; Morgan M Dancy; Laryssa McCloud; Mark S George; Harold A Sackeim
Journal:  Brain Stimul       Date:  2020-07-29       Impact factor: 8.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.